S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
The Day of Financial Reckoning Is Near (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
The 3-Stock Retirement Blueprint (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
The Day of Financial Reckoning Is Near (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
The 3-Stock Retirement Blueprint (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
The Day of Financial Reckoning Is Near (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
The 3-Stock Retirement Blueprint (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
The Day of Financial Reckoning Is Near (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
The 3-Stock Retirement Blueprint (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
US Dollar Replaced By "Biden Bucks"? (Ad)
NYSE:GSK

GSK - GSK Stock Forecast, Price & News

$34.70
-0.56 (-1.59%)
(As of 08/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$34.25
$34.93
50-Day Range
$34.70
$44.25
52-Week Range
$34.25
$46.97
Volume
11.46 million shs
Average Volume
5.68 million shs
Market Capitalization
$70.57 billion
P/E Ratio
11.49
Dividend Yield
4.74%
Price Target
N/A

GSK MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.30% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
N/A
News Sentiment
-0.26mentions of GSK in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
4.94%
From $3.44 to $3.61 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

762nd out of 1,122 stocks

Pharmaceutical Preparations Industry

381st out of 551 stocks

GSK stock logo

About GSK (NYSE:GSK) Stock

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

GSK Trading Down 1.6 %

Shares of GSK Stock opened at $34.70 on Thursday. The stock's 50-day moving average price is $41.49 and its 200-day moving average price is $43.01. GSK has a 12-month low of $34.25 and a 12-month high of $46.97. The stock has a market capitalization of $70.57 billion, a price-to-earnings ratio of 11.49, a price-to-earnings-growth ratio of 1.25 and a beta of 0.46. The company has a current ratio of 1.43, a quick ratio of 1.31 and a debt-to-equity ratio of 0.83.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 6th. Stockholders of record on Friday, August 19th will be given a dividend of $0.383 per share. This is an increase from GSK's previous quarterly dividend of $0.35. This represents a $1.53 dividend on an annualized basis and a dividend yield of 4.41%. The ex-dividend date of this dividend is Thursday, August 18th. GSK's dividend payout ratio is currently 55.30%.

Analyst Ratings Changes

Several equities analysts recently weighed in on GSK shares. TheStreet upgraded GSK from a "c+" rating to an "a-" rating in a research report on Friday, July 22nd. Barclays raised their price objective on shares of GSK from GBX 1,775 ($21.45) to GBX 1,800 ($21.75) in a research report on Friday, April 29th. JPMorgan Chase & Co. upped their target price on shares of GSK from GBX 1,740 ($21.02) to GBX 1,900 ($22.96) in a report on Thursday, April 28th. Citigroup reissued a "neutral" rating on shares of GSK in a report on Thursday, July 21st. Finally, UBS Group dropped their price objective on GSK from GBX 1,876 ($22.67) to GBX 1,850 ($22.35) in a research note on Wednesday, July 20th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, one has given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, GSK has a consensus rating of "Hold" and an average price target of $1,787.50.

Receive GSK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

GSK Stock News Headlines

GSK (NYSE:GSK) Sees Unusually-High Trading Volume
GSK plc (NYSE:GSK) Declares Dividend Increase - $0.38 Per Share
GSK (NYSE:GSK) Stock Rating Reaffirmed by Morgan Stanley
GSK plc (NYSE:GSK) Short Interest Update
See More Headlines
Receive GSK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

GSK Company Calendar

Last Earnings
2/02/2021
Ex-Dividend for 7/1 Dividend
5/19/2022
Dividend Payable
7/01/2022
Today
8/18/2022
Ex-Dividend for 10/6 Dividend
8/18/2022
Dividend Payable
10/06/2022
Next Earnings (Estimated)
10/26/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
90,096
Year Founded
2000

Profitability

Net Income
$6.03 billion
Pretax Margin
16.84%

Debt

Sales & Book Value

Annual Sales
$46.91 billion
Cash Flow
$3.59 per share
Book Value
$13.98 per share

Miscellaneous

Outstanding Shares
2,033,677,000
Free Float
1,830,309,000
Market Cap
$70.57 billion
Optionable
Optionable
Beta
0.46

Social Links


Key Executives

  • Ms. Emma N. Walmsley (Age 52)
    CEO & Director
    Comp: $4.59M
  • Mr. Iain James Mackay (Age 60)
    CFO & Exec. Director
    Comp: $3.41M
  • Dr. Hal V. Barron F.A.C.C. (Age 59)
    M.D., Chief Scientific Officer, Pres of R&D and Director
    Comp: $6.16M
  • Ms. Shobie Ramakrishnan
    Chief Digital & Technology Officer
  • Ms. Sarah Elton-Farr
    Head of Investor Relations
  • Mr. James Ford
    Sr. VP & Group Gen. Counsel of Legal & Compliance
  • Ms. Sally Jackson
    Sr. VP of Global Communications & CEO Office
  • Ms. Diana Conrad
    Chief People Officer
  • Mr. David Simon Redfern (Age 56)
    Chief Strategy Officer
  • Mr. Philip C. Thomson
    Pres of Global Affairs













GSK Stock - Frequently Asked Questions

Should I buy or sell GSK stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last year. There are currently 1 sell rating, 7 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.
View GSK analyst ratings
or view top-rated stocks.

How have GSK shares performed in 2022?

GSK's stock was trading at $44.10 at the start of the year. Since then, GSK stock has decreased by 21.3% and is now trading at $34.70.
View the best growth stocks for 2022 here
.

Are investors shorting GSK?

GSK saw a increase in short interest during the month of July. As of July 31st, there was short interest totaling 6,120,000 shares, an increase of 9.9% from the July 15th total of 5,570,000 shares. Based on an average daily volume of 4,690,000 shares, the days-to-cover ratio is currently 1.3 days. Approximately 0.3% of the company's shares are sold short.
View GSK's Short Interest
.

When is GSK's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 26th 2022.
View our GSK earnings forecast
.

How were GSK's earnings last quarter?

GSK plc (NYSE:GSK) posted its earnings results on Tuesday, February, 2nd. The pharmaceutical company reported $0.62 EPS for the quarter, missing analysts' consensus estimates of $0.64 by $0.02. The pharmaceutical company earned $8.74 billion during the quarter, compared to analyst estimates of $8.71 billion. GSK had a net margin of 12.91% and a trailing twelve-month return on equity of 27.84%. The business's quarterly revenue was down 1.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.39 earnings per share.
Read the conference call transcript
.

How often does GSK pay dividends? What is the dividend yield for GSK?

GSK announced a quarterly dividend on Wednesday, July 27th. Stockholders of record on Friday, August 19th will be paid a dividend of $0.383 per share on Thursday, October 6th. This represents a $1.53 annualized dividend and a yield of 4.41%. The ex-dividend date of this dividend is Thursday, August 18th. This is a positive change from the stock's previous quarterly dividend of $0.35.
Read our dividend analysis for GSK
.

Is GSK a good dividend stock?

GSK (NYSE:GSK) pays an annual dividend of $1.67 per share and currently has a dividend yield of 4.74%. GSK has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 55.30%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, GSK will have a dividend payout ratio of 46.26% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for GSK.

What guidance has GSK issued on next quarter's earnings?

GSK updated its FY 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $49.73 billion-$50.67 billion, compared to the consensus revenue estimate of $38.72 billion.

What other stocks do shareholders of GSK own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GSK investors own include AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Cisco Systems (CSCO), AbbVie (ABBV), Intel (INTC), Gilead Sciences (GILD), Walt Disney (DIS) and NVIDIA (NVDA).

What is GSK's stock symbol?

GSK trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

Who are GSK's major shareholders?

GSK's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Dodge & Cox (3.65%), FMR LLC (0.87%), Price T Rowe Associates Inc. MD (0.73%), Renaissance Technologies LLC (0.49%), JTC Employer Solutions Trustee Ltd (0.43%) and State Street Corp (0.42%).
View institutional ownership trends
.

How do I buy shares of GSK?

Shares of GSK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GSK's stock price today?

One share of GSK stock can currently be purchased for approximately $34.70.

How much money does GSK make?

GSK (NYSE:GSK) has a market capitalization of $70.57 billion and generates $46.91 billion in revenue each year. The pharmaceutical company earns $6.03 billion in net income (profit) each year or $3.02 on an earnings per share basis.

How many employees does GSK have?

The company employs 90,096 workers across the globe.

When was GSK founded?

GSK was founded in 2000.

How can I contact GSK?

GSK's mailing address is 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS. The official website for the company is www.gsk.com. The pharmaceutical company can be reached via phone at 442080475000, via email at gsk.investor-relations@gsk.com, or via fax at 44-20-8047-7807.

This page (NYSE:GSK) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.